Areas reviewed: In vivo tumor models, oncogenes and tumor suppressor genes in vivo, gene target validation, drug efficacy testing, human genetics/genomics, pharmacogenetics, pharmacogenomics, genetic risk, genotype to phenotype, gene therapy testing, and biomarker identification/development.

Sheri Holmen, PhD, Chair
Huntsman Cancer Institute/University of Utah
Salt Lake City, UT

Scott A. Oakes, MD, Vice Chair
University of California, San Francisco
San Francisco, CA

Jonathan Brody, PhD
Thomas Jefferson University
Philadelphia, PA

Mark Yat-Fung Chiang, MD, PhD
University of Michigan
Ann Arbor, MI

Ramana Davuluri, PhD
The Wistar Institute
Philadelphia, PA

Nancy Gargano, Stakeholder
Stevensville, MI

Scott Gerber, PhD
Dartmouth-Hitchcock Geisel School of Medicine
Lebanon, New Hampshire

Steven Grossman, MD, PhD
Virginia Commonwealth University
Richmond, VA

Amir A. Jazaeri, MD
University of Virginia
Charlottesville, VA

Yibin Kang, PhD
Princeton University
Princeton, NJ

Ruth O'Regan, MD
Emory University
Atlanta, GA

W. Kimryn Rathmell, MD, PhD
University of North Carolina
Chapel Hill, NC

Marilyn Rex, Stakeholder
San Mateo, CA

Ralph Scully, MD, PhD
Beth Israel Deaconess
Boston, MA

Alejandro Sweet-Cordero, MD
Stanford University
Stanford, CA

Amanda Toland, PhD
The Ohio State University
Columbus, OH

Kathryn Wikenheiser-Brokamp, MD, PhD
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH